CB Company

As of April 1, 2024, Germany has decriminalized cannabis: possession, consumption, and personal cultivation are now penalty-free. Starting July 1, 2024, cultivation associations (colloquially known as "CSCs, Cannabis Social Clubs") are allowed to cultivate cannabis for up to 500 members and distribute it to their members non-profitably. Additionally, medical cannabis is no longer subject to the Na...

As of July 1, 2024, cultivation associations are allowed to grow cannabis for their up to 500 members and sell it to them without profit. As the "closing panels" of the preceding Intensive Seminar for Cultivation Associations (Cannabis Competence Days, CKT, Wednesday, June 12 – Thursday, June 13), experts from the fields of law, marketing, competition, and cultivation technology delve into the cha...

In addition to the recent partial legalization of cannabis in Germany, there is a lot happening around the globe: From Dutch and Swiss pilot projects to the advancements and plans in the Czech Republic, Poland, and other European countries, to Thailand, where politics may be vacillating, yet the cannabis economy is simultaneously flourishing and growing. Which country will legalize next? What are...

With the new CanG, Germany has removed medical cannabis from the narcotics list. Doctors can now prescribe cannabis to patients without extensive bureaucratic hurdles, and at the same time, the cultivation of medical cannabis in Germany is permitted. What impact does this have on the market regarding prescription numbers for private and insured patients? How do patients benefit from this? What do...

The new CanG law has opened the floodgates for proactive marketing towards new cannabis patients. Prescriptions are now available starting from 1€, necessary consultations and the shipping of medical cannabis take place entirely online, and rappers are promoting the whole thing. Is this in the interests of healthcare and patients? What do healthcare professionals and pharmaceutical companies say a...

Multiple informed choices in facility design have to be made by growers/investors. First of all the growing facility going for a indoor facility or a greenhouse facility. But secondly climate, light, substrate all are connected and as a consequence having impact on energy efficiency. All will be discussed in this panel with experts to achieve successful discussions on facility set-up. Language: En...

IPM does not offer a universal remedy; rather, it involves the integration of customized strategies suited to individual circumstances. Through the implementation of these strategies, cultivators equip themselves with a robust methodology to effectively manage pests, pathogens, viruses and viroids. Don't miss this opportunity to gain valuable insights into the realm of medical cannabis cultivation...

Since 2021, Max has been responsible for the lighting design and simulation of all major projects as Sales Application Engineer at SANlight GmbH. Here he can draw on his experience in climate and irrigation planning and provides customers with a holistic view of the project. Taking into account all influencing factors and components in a project of this magnitude is the key to success. Optimising...

This masterclass delves into the crucial role of genetics in cannabis production. Genetics dictate the quality, consistency, and cost of products—key factors for consumers. The panellists will discuss the surge in home cultivation in Europe, the seed versus tissue culture debate, and the complexities of aligning consumer tastes with genetic stability. Additionally, the session explores the rise of...

There are over 200 medical cannabis products available in Germany, yet only 2 of them have market authorisation, why is that? Today's panel will be discussing why such few companies have pursued drug development and market authorisation. What role will approved finished drugs play in the future and what is the impact of legalisation of recreational cannabis? Will legislation affect the type of pro...

Building medical cannabis companies and brands that resonate with patients can be extremely difficult in highly regulated markets. Acquiring new patients can be even more challenging, given the stringent restrictions on advertising and marketing. This situation presents a unique set of challenges for medical cannabis companies across Europe. In this masterclass, participants will hear from some of...

Language: English Speaker Dr. Pavel Kubu MD (Speaker), Chain Pharmaceuticals GmbH, Chief Information Officer

On the basis of results from qualitative interviews and an online survey online survey, the prejudices and practical problems faced by people practical problems people who use cannabis for medical reasons still face people who use cannabis for medical reasons still have to deal with, even in times of (theoretically) legal supply. There is a considerable number of people who, despite manifest sympt...

Join us as we introduce a diverse panel, bringing together different perspectives of the industry, to provide their insights on what the removal of cannabis from the German Narcotics List really means. What changes are to be expected by patients, pharmacists, physicians and the industry as a whole? Does the reclassification provide opportunities for the industry or is it just another reason for hy...

The cannabis plant uses a wide palette of terpenes and minor cannabinoids to produce its array of effects. But for consumers and producers of whole plant products, they are plagued by the inconsistencies inherent to a botanical product. The winning cannabinoid products of the future will contain unique formulations of terpenes and cannabinoids for directed consistent effects. Lex Pelger will highl...

In the landscape of CBD, a significant hurdle emerges - only a mere 6% of a dose is accessible for the body's absorption, as indicated by a report from the World Health Organization (WHO). This fact beckons a compelling question: How can we unlock enhanced CBD absorption and unleash its full potential? Dr. Sung-Min Pyo, expert in pharmaceutical formulation and frequent guest lecturer at globally r...

From ADAC e. V. to Cannabis Club e. V. - What legal requirements should be created today in Pillar I in order to successfully implement social clubs? What do prospective cannabis club associations need to know and observe? And is an exit or transition to a model project possible later, when Pillar II comes? An analysis of the law on associations, companies and the upcoming law. Let's regulate! Lan...

A comprehensive understanding of the current position, and where we go from here. The regulation of cannabis for adult use in Europe presents a myriad of challenges for member states. While some are adopting an incremental approach to address the issue, the need for a cohesive and comprehensive regulatory framework at the European level becomes increasingly apparent. Harmonising cannabis regulatio...

Internationally for many years across different ethnic around the world, Cannabis smokers have been blending Tabacco leaves within their Marijuana smoking habits. Since the development of the Cannabis industry in the US in the late 90's, two main cannabinoids have became popular in this emerging smoking/vaping industry. The active compound called THC (Delta 9-Tetrahydrocannabinol) with intense men...

In order to meet the regulatory requirements (Novel Food application) and to open up the outstanding prospects of the CBD market (food and nutritional supplements) for our members and partners, EIHA is conducting a Novel Food application for CBD isolates and hemp extracts. The subsidiary responsible for this, EIHA projects GmbH, is investing a total of approx. 3.5 million EUR in the necessary toxi...

CBD - A Question of Demarcation? CBD: Popular Among Consumers, a Regulatory Challenge. After the CBD hype of recent years, companies are facing increasing challenges in the market. The marketability of products is dependent on category-appropriate marketing. The accusation of misuse and the controlled substances status of industrial hemp still play a role. What does the future hold for industrial...

Delving into worldwide investments in both recreational and medical cannabis, this panel discussion will tackle the complexities of investing across varied regions and sectors, gleaning insights from seasoned cannabis investors around the world. The panel will unpack international investment nuances and spotlight European-specific hurdles, offering advice for entrepreneurs in search of funding. La...

Big tobacco cannot ignore the rise and potential of cannabis as a replacement for tobacco, but what is their right to win? What are some challenges that big tobacco companies face when entering or considering the cannabis industry? This panel will delve into the ethical considerations and historical backdrop. Drawing comparisons in trade, production, and taxation across these industries, the conve...

Where there's a will, there's no way? According to the German legislature, the will exists to re-regulate legal industries around the hemp plant in a new and solution-oriented manner. Only seemingly are the possibilities lacking. The step backwards after the initial framework paper in the consumer goods market, the absurd BtM sword of Damocles for all industrial hemp actors, the uncertain future f...

Model projects are a legitimate means of the political and regulatory process to explore new markets, your products and services. What approaches have proven successful in the past and what new approaches can we see among European neighbours? The political will to end the prohibition of cannabis beyond medicine can be seen in many European countries. How will Germany position itself and how can th...